Fort Washington Investment Advisors Inc. OH Acquires 1,596 Shares of Haemonetics Corporation $HAE

Fort Washington Investment Advisors Inc. OH increased its holdings in Haemonetics Corporation (NYSE:HAE) by 0.3% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 518,682 shares of the medical instruments supplier’s stock after purchasing an additional 1,596 shares during the quarter. Fort Washington Investment Advisors Inc. OH owned approximately 1.08% of Haemonetics worth $38,699,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. GAMMA Investing LLC boosted its position in Haemonetics by 59.4% during the second quarter. GAMMA Investing LLC now owns 443 shares of the medical instruments supplier’s stock valued at $33,000 after acquiring an additional 165 shares during the last quarter. Quarry LP raised its holdings in shares of Haemonetics by 63.4% during the first quarter. Quarry LP now owns 495 shares of the medical instruments supplier’s stock valued at $31,000 after purchasing an additional 192 shares during the period. Louisiana State Employees Retirement System raised its holdings in shares of Haemonetics by 1.4% during the first quarter. Louisiana State Employees Retirement System now owns 14,100 shares of the medical instruments supplier’s stock valued at $896,000 after purchasing an additional 200 shares during the period. Inspire Investing LLC raised its holdings in shares of Haemonetics by 5.9% during the first quarter. Inspire Investing LLC now owns 5,441 shares of the medical instruments supplier’s stock valued at $346,000 after purchasing an additional 304 shares during the period. Finally, UMB Bank n.a. raised its holdings in shares of Haemonetics by 91.7% during the second quarter. UMB Bank n.a. now owns 669 shares of the medical instruments supplier’s stock valued at $50,000 after purchasing an additional 320 shares during the period. Institutional investors own 99.67% of the company’s stock.

Haemonetics Stock Up 1.1%

HAE opened at $48.20 on Friday. The company has a 50 day moving average of $58.73 and a 200 day moving average of $64.24. The company has a market cap of $2.32 billion, a PE ratio of 14.74, a price-to-earnings-growth ratio of 0.89 and a beta of 0.39. Haemonetics Corporation has a 12 month low of $47.31 and a 12 month high of $94.99. The company has a current ratio of 1.72, a quick ratio of 1.04 and a debt-to-equity ratio of 1.04.

Haemonetics (NYSE:HAE) last released its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $1.10 EPS for the quarter, topping the consensus estimate of $1.01 by $0.09. The company had revenue of $321.39 million during the quarter, compared to the consensus estimate of $305.12 million. Haemonetics had a net margin of 12.14% and a return on equity of 26.64%. Haemonetics’s revenue for the quarter was down 4.4% on a year-over-year basis. During the same period last year, the firm earned $1.02 EPS. Haemonetics has set its FY 2026 guidance at 4.700-5.00 EPS. On average, sell-side analysts expect that Haemonetics Corporation will post 4.55 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the stock. Citigroup upgraded shares of Haemonetics from a “neutral” rating to a “buy” rating and set a $90.00 target price on the stock in a report on Wednesday, July 9th. Raymond James Financial lowered shares of Haemonetics from a “strong-buy” rating to an “outperform” rating and lowered their target price for the stock from $105.00 to $78.00 in a report on Monday, August 11th. Mizuho decreased their price objective on shares of Haemonetics from $90.00 to $70.00 and set an “outperform” rating for the company in a research note on Friday, August 8th. Baird R W upgraded shares of Haemonetics to a “strong-buy” rating in a research note on Wednesday, June 25th. Finally, JPMorgan Chase & Co. reiterated a “neutral” rating and issued a $62.00 price objective (down previously from $85.00) on shares of Haemonetics in a research note on Friday, August 8th. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $78.78.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.